Small Stocks, Big Money™

XTI Aerospace (Nasdaq: XTIA) continues to build momentum with the announcement of key Q2 2025 engineering milestones for its groundbreaking TriFan 600 xVTOL aircraft, including the first flight of its new subscale model "Sparrow" and critical supplier selections. With pre-sales slated to reopen later this year, XTI is advancing toward reshaping regional air travel with a revolutionary solution boasting helicopter-like versatility and jet-like speed.

Connect Biopharma (Nasdaq: CNTB) announced four key presentations at the upcoming ATS 2025 Conference, spotlighting rademikibart’s promising efficacy in asthma and COPD patients. Backed by rapid lung function improvements and robust biomarker data, the Company is accelerating rademikibart’s development with parallel Phase 2 trials set to initiate in Q2 2025, addressing a U.S. market of over 2.3 million patients annually experiencing acute exacerbations.

Better Choice Company (NYSE American: BTTR) completed its transformative merger with SRx Health and closed an $8.8 million private placement priced above market, positioning the newly renamed SRx Health Solutions Inc. as a global leader in health and wellness for pets, people, and families. The strategic combination and capital raise set the stage for accelerated growth across a rapidly expanding wellness market. The company’s ticker will change to SRXH, effective Wednesday, April 30, 2025.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) announced preliminary survey results suggesting nearly 3 million Americans may have babesiosis—vastly exceeding CDC estimates of just 73,000 cases. Highlighting a significant underdiagnosis of this serious tick-borne disease, the findings support the growing market need for effective treatments like 60 Degrees' ARAKODA®, currently being evaluated in clinical trials for persistent Babesia infections.